|
Match
|
Document |
Document Title |
|
|
US20090280176 |
CONTROLLED RELEASE FORMULATIONS OF ALPRAZOLAM
A controlled release formulation of alprazolam for once a day administration to a mammalian subject, which formulation releases alprazolam along a pre-determined release profile, is provided.
|
|
|
US20090280175 |
Multilayer Proton Pump Inhibitor Tablets
Multilayer tablets of a proton pump inhibitor essentially bioequivalent in terms of plasma C max and AUC to capsules and/or tablets consisting of multiple unit pellets of the proton pump inhibitor...
|
|
|
US20090280174 |
Solid Pharmaceutical Preparation
It is intended to provide a long-acting solid pharmaceutical preparation which has an immediate release part and a sustained release part containing tramadol or a pharmaceutically acceptable salt...
|
|
|
US20090269402 |
MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE
The present invention relates to a modified release composition of at least one form of venlafaxine, which is a delayed controlled release composition. The composition comprises a core comprising...
|
|
|
US20090263481 |
LEVETIRACETAM FORMULATIONS
Pharmaceutical formulations comprising levetiracetam and having an inner solid phase and outer continuous phase, wherein one or both of the phases comprise at least one hydrophobic material,...
|
|
|
US20090263475 |
DEXLANSOPRAZOLE COMPOSITIONS
Premixes of dexlansoprazole with pharmaceutical excipients, processes for preparing premixes, pharmaceutical formulations containing the premixes, and their use in treatment of erosive esophagitis...
|
|
|
US20090258067 |
MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE
The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition...
|
|
|
US20090226517 |
PHARMACEUTICAL FORMULATIONS COMPRISING DULOXETINE
A pharmaceutical formulation comprising: a core particle comprising duloxetine or its salts; a separating layer; and an enteric layer disposed over the separating layer; wherein the formulation...
|
|
|
US20090208572 |
ORAL CONTROLLED RELEASE TABLET
A method of reducing the risk of alcohol-induced dose-dumping of a therapeutically active ingredient comprising administering to human subjects who have ingested alcohol an oral controlled release...
|
|
|
US20090196922 |
BILAYER TABLET FOR PREVENTING CARDIOVASCULAR EVENTS
The present invention relates to a bilayer tablet which comprises a compartment containing a pharmaceutically acceptable simvastatin compound as its active ingredient; and at the same time a...
|
|
|
US20090196889 |
CONTROLLED ABSORPTION OF STATINS IN THE INTESTINE
The present invention provides a controlled absorption formulation in which modified release of active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The...
|
|
|
US20090186082 |
METHOD OF MANUFACTURING MODIFIED RELEASE DOSAGE FORMS
In one embodiment, a dosage form comprises: (a) at least one active ingredient; (b) a molded core which is solid at room temperature; and (c) a shell which is in contact with at least a portion of...
|
|
|
US20090181084 |
Oral fast-disintegrating tablet including particles of slowly-releaseable ascorbic acid
An oral fast-disintegrating tablet includes many tiny particles of slowly-releasable ascorbic acid, and a fast-disintegrating ingredient mixed with the many tiny particles that are dispersedly...
|
|
|
US20090175939 |
PHARMACEUTICAL COMPOSITIONS
Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.
|
|
|
US20090175938 |
Controlled Release Flurbiprofen and Muscle Relaxant Combinations
This invention is a novel controlled release (CR) flurbiprofen and muscle relaxant combinations for oral administration with anti-inflammatory, analgesic, myorelaxant activity and methods of its...
|
|
|
US20090162434 |
MESALAZINE TABLET
Disclosed are mesalazine tablets and a method for their preparation. The mesalazine tablets comprise a tablet core, a first coating layer, and a second coating layer. The tablet core comprises...
|
|
|
US20090155358 |
PHARMACEUTICAL COMPOSITIONS OF SHORT-ACTING HYPNOTIC AGENTS IN MODIFIED-RELEASE FORMS AND THE PROCEDURES TO PREPARE THE MENTIONED FORMULATION
This application refers to a modified-release pharmaceutical composition containing, as the active agent, a short-acting hypnotic agent or a pharmaceutically acceptable salt thereof, comprising two...
|
|
|
US20090130208 |
Modified release niacin formulations
Modified release niacin formulations, methods for making the formulations, and methods of using the formulations.
|
|
|
US20090130207 |
Pharmaceutical Tablets Having a Relatively Inactive Segment
An immediate release drug containing pharmaceutical tablet adapted for accurate breaking which has two or more segments with at least one segment containing a drug.
|
|
|
US20090123541 |
Pharmaceutical Composition
The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising:
(a) a highly soluble high dose active ingredient...
|
|
|
US20090117184 |
Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception
Gestagens, preferably dienogest, chlormadinone acetate or levonorgestrel, in combination with estrogens, for example ethinylestradiol, 17β-estradiol or estradiol valerate, and one or more...
|
|
|
US20090117183 |
ORAL CONTRACEPTIVE CONTAINING A GESTAGEN AND AN ESTROGEN COMBINED WITH PHARMACEUTICALLY ACCEPTABLE AUXILIARY AGENTS AND/OR EXCIPIENTS, BUT NOT CONTAINING LACTOSE, AND METHOD OF MAKING SAME
The method produces a lactose-free oral contraceptive composition containing a combination of a gestagen and an estrogen together with one or more pharmaceutically acceptable auxiliary agents...
|
|
|
US20090092658 |
NOVEL FORMULATIONS OF PROTON PUMP INHIBITORS AND METHODS OF USING THESE FORMULATIONS
The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability,...
|
|
|
US20090087488 |
GALANTAMINE-CONTAINING CONTROLLED RELEASE ORAL DOSAGE FORMS, PROCESSES FOR THE PREPARATION THEREOF AND USE OF THE MANUFACTURE OF A MEDICAMENT
The present invention relates to controlled release oral dosage forms of galantamine or acceptable salts thereof and processes for the preparation thereof.
|
|
|
US20090068264 |
Clinical Applications of Tetrahydrobiopterin, Lipoic Acid and Their Salts and Methods of Preparing Tetrahydrobiopterin Bis-Lipoate
Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or...
|
|
|
US20090035374 |
METHOD OF MAKING A SINGLE-STAGE PHARMACEUTICAL PREPARATION FOR ORAL THERAPY TO REGULATE BLOOD PRESSURE AND KIT CONTAINING SAME
The single-stage oral contraceptive preparation contains at least 21 daily dosage units, which each contain a contraceptive combination of 2.0 mg of dienogest (not an aidosterone antognist) and...
|
|
|
US20090035373 |
PHARMACEUTICAL COMPOSITION FOR CONTRACEPTION AND BLOOD PRESSURE REGULATION, KIT FOR CONTRACEPTION CONTAINING SAME AND METHOD OF PRODUCTION OF SAME
The pharmaceutical composition for contraception and regulating blood pressure includes daily dosage units, which contain 2.0 mg of dienogest and 0.030 mg of ethinyl estradiol, 2.0 mg of dienogest...
|
|
|
US20090028942 |
Sustained release compositions of alfuzosin
The invention relates to sustained release compositions of alfuzosin or pharmaceutically acceptable salts thereof that include one or more functional layers. The functional layer includes alfuzosin...
|
|
|
US20090022798 |
FORMULATIONS OF NONOPIOID AND CONFINED OPIOID ANALGESICS
The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially...
|
|
|
US20090011019 |
PHARMACEUTICAL COMPOSITIONS FOR GASTROINTESTINAL DRUG DELIVERY
A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally...
|
|
|
US20090011018 |
Sustained release formulation for tacrolimus
A sustained release pharmaceutical composition for tacrolimus, comprising a solid dispersion containing tacrolimus or a pharmaceutically acceptable salt thereof, and a carrier for a sustained...
|
|
|
US20080311201 |
MODIFIED RELEASE SOLID OR SEMI-SOLID DOSAGE FORMS
A solid or semi-solid pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient...
|
|
|
US20080311191 |
Multi-Layer Tablets and Bioadhesive Dosage Forms
Bioadhesives coatings increase the gastrointestinal retention time of orally-ingested medicaments. Certain bioadhesive coatings producing a fracture strength of at least 100 N/m 2 , as measured on...
|
|
|
US20080299197 |
Triple Combination Release Multi-Layered Tablet
This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet ( 1...
|
|
|
US20080299189 |
CONTROLLED RELEASE DOPAMINE AGONIST COMPOSITIONS
The present invention relates to a multiphase release oral pharmaceutical formulation having a dopamine agonist as an active ingredient. The multiphase composition comprises at least two different...
|
|
|
US20080292702 |
Solid Dispersion Comprising An Active Ingredient Having A Low Melting Point And Tablet For Oral Administration Comprising Same
A fused solid dispersion comprising an active ingredient having a melting point of 800 C or below and a pharmaceutically acceptable absorbent having a specific surface area ranging from 20 to 400...
|
|
|
US20080292696 |
Enteric Sustained-Release Tablet Comprising Paroxetine
The present invention relates to an enteric, sustained-release tablet comprising paroxetine or a hydrates or anhydrides of a pharmaceutically acceptable salt thereof as active substance, more...
|
|
|
US20080286344 |
Solid form
A solid form comprising at least one film enrobing a compacted fill material wherein:
i) the compacted fill material comprises at least one active material; ii) the solid form shows a weight...
|
|
|
US20080279934 |
EXTENDED RELEASE FORMULATION FOR PRALNACASAN
This invention relates to a sustained release tablet comprising at least two layers, wherein at least one layer rapidly releases pralnacasan and the other layer releases pralnacasan in a delayed...
|
|
|
US20080274181 |
BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS
Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
|
|
|
US20080268047 |
Controlled Release Multiple Layer Coatings
A process for making controlled release pharmaceutical formulations is provided, which comprises supplying a plurality of solutions with syringe pumps for fluid bed coating, coating a substrate...
|
|
|
US20080268046 |
Formulations with Controlled Release of Active Ingredient
The present invention relates to novel pharmaceutical dosage forms with controlled release of active ingredient which comprise the PDE 5 inhibitor vardenafil and/or pharmaceutically acceptable...
|
|
|
US20080260825 |
Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some...
|
|
|
US20080260817 |
Compositions for the Treatment of Inflammation and Pain Using a Combination of a Cox-2 Selective Inhibitor and a Ltb4 Receptor Antagonist
The present invention provides a therapeutic composition comprising a COX-2 selective inhibitor or a prodrug thereof and an LTB 4 receptor antagonist. A method is provided for the use of such...
|
|
|
US20080254121 |
Multi-layer melatonin composition
A multi-layered solid dosage form for oral administration for a multi-phasic controlled release of Melatonin is described. The solid dosage form is useful as a composition to promote and maintain a...
|
|
|
US20080248114 |
ORAL OSMOTIC DRUG DELIVERY SYSTEM
The present invention relates, generally, to oral osmotic drug delivery systems, methods of preparing same, and methods of using oral osmotic drug delivery systems to provide controlled delivery of...
|
|
|
US20080206335 |
MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR FORMULATIONS
A multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) formulation for oral administration comprises particles of said SSRI or a pharmaceutically acceptable salt...
|
|
|
US20080199522 |
TIMED-RELEASE COMPRESSION-COATED SOLID COMPOSITION FOR ORAL ADMINISTRATION
The present invention was completed based on these discoveries and relates to in a hydrogel-forming compression-coated solid pharmaceutical preparation comprising a core tablet containing drug and...
|
|
|
US20080193522 |
Use of Polymer Mixtures For the Production of Coated Pharmaceutical Formulations and Pharmaceutical Formulation With Mixed Polymeric Coating
The invention relates to the use of mixture of 2 to 60 wt. % of one or more polymers (I) with 40 to 98 wt. % of one or more polymers (II), whereby the polymer (I) is a (meth)acrylate copolymer,...
|
|
|
US20080187589 |
MULTI-MODAL DELIVERY VIA TRANSMUCOSAL AND GASTRO-INTESTINAL ABSORPTION OF ANTIHISTAMINES AND SYMPTOM RELIEF
A multi-modal absorption, medicine-delivery lozenge is provided. The lozenge includes a lozenge base for oral administration into a user's mouth, a medicinal active ingredient including an...
|